记者了解到，南京明基胰腺病医院拥有"一体化病房"，开放床位180张，包括7张HDU高依赖病床和14 张日间化疗床位，拥有省内领先的内镜中心和介入治疗中心，年完成各类胰腺手术600余例，手术切除 率、死亡率、并发症发生率、生存率等项指标达到国际先进水平。南京明基胰腺病医院同时也为国际胰 腺组织的合作单位，与国际知名的里斯本Champalimaud胰腺癌中心共同成立了明基-香帕里梦德胰腺癌 研究所。 扬子晚报/紫牛新闻记者许倩倩 5月12日，南京明基胰腺病医院正式揭牌，这是在医院胰腺中心基础上发展成立的胰腺疾病现代化专科 医院。"在建设规范上，我们愿意作为实验田，为更多的专病医院提供创新模板。"南京明基医院院长于 振坤表示，胰腺病医院的揭牌也意味着南京明基医院在强专科建设上走出了新的一步。 据悉，南京明基胰腺病医院由国际知名胰腺外科专家苗毅教授担任院长，创新性地建立以胰腺疾病为目 标的多学科一体化融合医疗的专科医院。他介绍，这里提供专业高品质的多学科"一站式、实时、全过 程"医疗服务，有机整合了外科、重症监护、内科、内镜、化疗、支持治疗、麻醉、放射介入、日间诊 疗、护理、病理、营养、药学、临床数据库、生物样本库、 ...

深夜通报。 5月11日，央视财经报道某些医院在为厨师、外卖员、护工等从业人员办理健康证的体检过程中，存在种种违规情况， 规章制度形同虚设。其中涉及郑州市个别医疗机构从业人员健康证明办理有关问题。 12日晚，郑州市卫健委发布"健康证"办理有关问题查处进展情况的通报。 经核查，二七爱新中医院（原二七爱康中医院）、金水慧慈医院、金水福德堂中医院存在未按照有碍食品安全及公共 卫生疾病目录项目开展体检的违规行为；金水慧慈医院还存在未经医师亲自诊查出具健康证明的违规行为。 所在辖区卫生健康行政部门已责令上述医疗机构暂停从业人员健康体检业务并依法立案查处，将依据相关法律法规的 规定，进一步作出警告、罚款、停止相应执业活动的行政处罚。 点击关键字可查看 潜望系列深度报道丨 股事会专栏 丨 投资小红书 丨 e公司调查 丨 时报会客厅 丨 十大明星私募访谈 丨 昨夜，大 爆发！中概股飙升！特朗普签署新的行政令 丨 深夜突发！长和回应港口交易！ 丨 华为，热门赛道大消息！ 丨 深 夜，大涨！ 丨 央行、证监会等联合发布！ 丨 突发重磅！港股、A50直线飙升 丨 飙升近13000点！这国股市暴涨 至熔断！ 丨 301302，1分钟拉 ...

身着蓝白色工作服，快步穿行于病床间，一边检查监护仪数据，一边回应家属询问……36岁的陈意，已在急诊科工作12年。对他而言，连轴转已 是"家常便饭"。"在急诊科当护士，特别考验临床思维和应变能力。每天都不清楚下一刻会遇到怎样的病人。"陈意说。 新华社成都5月11日电（记者赵怡宁、董小红、杨华）监护仪的滴滴声、急促的脚步声、医护人员的沟通声……在急诊科，一扇365天24小时敞开 的大门，是许多危急患者的"生命通道"。 在"5·12"国际护士节来临之际，记者走近四川大学华西医院急诊护理科的护士们，倾听这群急诊护理"尖兵"背后的故事。 2025年5月9日，四川大学华西医院急诊科护士陈意正在护理病人。新华社记者 赵怡宁 摄 来自四川仁寿县的陈意决定当一名护士，源于2008年汶川地震中的经历。 当时还在读高中的他，目睹医护人员冒着余震抢救伤员的情景后，深受震撼。"护士紧紧握住伤员的手，给伤员清理换药，给大家带来生的希望； 从此之后，护士这份工作就在我心中生根发芽。"陈意说，2013年，他如愿进入四川大学华西医院急诊科，实现了自己的梦想。 与其他科室不同，急诊科危急重症患者多，护理工作节奏快，更锻炼人。"急诊科的护理工作虽 ...

沈奇伟带领医院职工一同锻炼。新华社记者 许东远 摄 新华社上海5月11日电（记者袁全、许东远）"工作太忙，没时间运动。""下班了，我只想'躺平'。""外卖热量高？但我不想自己做饭。"这些困扰 现代人的减肥难题，同样存在于医生的白大褂之下。 5月11日"中国肥胖日"前夕，记者走进复旦大学附属华山医院，为应对忙碌的日常中难以避免的"过劳肥"，这里的医护人员选择以科学为盾、以互 助为矛，在院内一个名为"30斤俱乐部"的组织中开启了一场自我革新的健康之战。 清晨7点15分，记者来到华山医院浦东院区的运动康复中心，"30斤俱乐部"的招牌下已聚集了十余名身着白大褂或洗手衣的医护人员。运动医学科 主管技师孙扬手持计时器，一边催促同事加快动作，一边示范着标准姿势："大家抓紧时间动起来，门诊开始前准时结束！"热身、拉伸、哑铃训 练……平日手术台上沉稳干练的医生们，此刻在瑜伽垫上发出阵阵"惨叫"。"坚持住，还有两组！"孙扬的鼓励声夹杂着喘息，汗水浸透的T恤成了 这群"减肥战友"无声的勋章。 这场每周雷打不动的晨练，源自两位外科医生"化脂肪为友谊"的奇妙碰撞。 "前几年忙到没时间关注身体，体重飙升，体检指标全亮红灯。"肥胖疝外科副 ...

自2025年2月新泰市人民医院《多科室联合提升老年患者的心理健康水平》项目启动以来，医院医学心 理科以创新协作模式为核心，通过跨学科资源整合、标准化流程优化及全员能力提升三大抓手，系统性 推进老年心理健康服务体系提质升级，为县域老年友善型医院建设打造新标杆。 医学心理科以肿瘤科、心内科、消化内科等老年高需求科室为支点，构建"会诊-干预-教育"一体化服务 网络。面向肿瘤科，通过系统性专题研修课程，深度剖析老年肿瘤患者失眠、焦虑等隐匿性心理问题的 临床特征，创新性提出"心理状态-治疗依从性-预后效果"三者之间的关系，并与肿瘤科团队成员就目前 科室常见心理问题及相关提问展开探讨，实现心理健康与肿瘤治疗的动态衔接。针对消化内科、心内科 患者高发的躯体形式障碍、躯体忧虑等问题，开展"胃肠症状心理归因鉴别""双心医学"相关讲课，通过 典型病例教学、系统症状对比等，进一步提升了消化内科、心内科医护人员对功能性症状的识别鉴别能 力，并向其宣传心理健康对消化内科、心内科相关疾病治疗的优势，推动"身心同治"理念在内科的相关 工作中落地生根。 同年4月28日，在我院举办的"新医大讲堂"学术活动中，李天超副主任以《洞察心灵之疾—常见 ...

Overview - The company announced a supplementary notice regarding the payment of guarantee fees to related parties and the associated transactions [1] Transaction Details - The board of directors approved a proposal for the company to pay guarantee fees to related parties, which will be submitted for review at the 2024 annual general meeting [1] - The company’s wholly-owned subsidiary, Guizhou Daqin Tumor Hospital Co., Ltd., will receive a fixed asset loan from the Agricultural Development Bank of China, with guarantees provided by Guizhou Chitianhua Group and Zunyi Tiantong Plastic Co., Ltd. [1] - The guarantee fee payment is based on the assessed value of the collateral provided for the loan [2] Asset Evaluation - The assessed value of the collateral, which includes 66 properties and commercial spaces, is determined to be 200.8363 million yuan, reflecting a decrease of 22.23% from the previous bank assessment [2] - The decline in assessed value is attributed to reduced usable life of the assets and a sluggish real estate market [2] Adjusted Guarantee Fee Structure - The pricing basis for the guarantee fee will be adjusted according to the new assessed value [3] - The maximum estimated total guarantee fee is now capped at 34.6443 million yuan, calculated based on the new assessed value over a maximum period of 11.5 years [5] Future Implications - The adjustment in the assessed value of the collateral will lead to a reduction in the guarantee fees payable by the company [5] - The company aims to negotiate with the Agricultural Development Bank to release the guarantees by 2028, contingent on the hospital's operational performance [5]

近日，第十四届胸痛中心大会授牌仪式在苏州举行，邹城市人民医院胸痛中心顺利通过中国胸痛中心总 部再认证审核授牌。 邹城市人民医院胸痛中心成立于2018年，整合了心血管内科、心外科、院前急救科、急诊科、介入导管 室、门诊部、心电图室等多学科，通力合作实施诊治，制定《邹城市人民医院急性胸痛患者诊治流程》 《胸痛中心院内管理架构》《胸痛中心工作模式架构图》《胸痛中心救治小组成员构成及职责》《胸痛 中心建设管理及质控指导方案》《胸痛中心各相关工作奖惩规定》等规章制度，严格按照国家胸痛中心 建设标准，不断推进和完善各项流程。2021年通过国家标准版胸痛中心认证，获批中国胸痛中心并予以 授牌。通过认证后，该院胸痛中心始终严格按照建设标准对中心常态化运行，每年定期举行胸痛中心联 合例会、质量分析会、典型病历讨论会，不断整合资源，优化各项救治流程，积极创建急性胸痛区域救 治网络。 2023年启动邹城市心电一张网行动，铺设了县-乡-村全覆盖的心电一张网，7家乡镇卫生院通过了基层 胸痛救治单元评审，以心电一张网为依托，将紧密型医联体推广及下沉，提高了专科区域整体救治疗水 平，急性胸痛转诊率 80%，邹城市急性心肌梗死再灌注治疗率9 ...

Summary of Key Points from the Conference Call Industry Overview - The pharmaceutical industry faced revenue pressure in Q1 2025, with varied performance across segments. Biologics grew by 12% driven by overseas business, hospitals increased by 6.7%, and medical consumables rose by 1.8% [1][3][4]. Core Insights and Arguments - **CXO and IVD Focus**: Public fund holdings indicate that CXO (Contract Research Organization) and IVD (In Vitro Diagnostics) are key market focuses. Companies like WuXi AppTec and Kelun are benefiting from overseas business, with high capacity utilization [1][4]. - **CXO Characteristics**: The CXO sector in Q1 2025 showed strong overseas-driven growth, with improved domestic new orders but overall performance lagging behind international results. Leading companies exhibit strong stability, while smaller firms are relatively weaker [5][6]. - **IVD Sector Decline**: The IVD industry experienced negative growth in Q1 2025, with reagent consumption declining year-on-year. The chemiluminescence sector performed better due to import substitution, while companies like Mindray faced challenges from mature business impacts [1][9]. - **Policy Impact on IVD**: Domestic policies such as DRG 2.0 and medical service price adjustments significantly affected the IVD sector, leading to decreased testing prices and reduced profitability for channels, impacting overall testing volumes [10]. Additional Important Insights - **Medical Equipment Recovery**: The medical equipment sector showed signs of recovery, with a more than 60% year-on-year increase in procurement in Q1 2025, particularly in tertiary hospitals. Expectations for better performance in the second half of the year are optimistic [1][16]. - **Investment Opportunities**: Areas with potential for high growth include innovative drugs, CXO, biologics, and hospital services, driven by new product launches and increased international market demand [7][21]. - **Market Trends**: The medical device sector is expected to improve in the second half of 2025, with procurement demand recovering after a significant decline in 2024 [14][16]. - **International Market Influence**: Chinese medical device companies are seeing significant contributions from international markets, with notable growth rates in overseas business for companies like Mindray and United Imaging [17]. Fund Holdings and Market Sentiment - **Biopharmaceutical Fund Allocation**: In Q1 2025, biopharmaceuticals accounted for 9.2% of the top ten fund holdings, indicating a positive sentiment towards the sector despite a historical trend of under-allocation since 2021 [18][19]. - **Hospital Sector Holdings**: The hospital sector saw a drastic reduction in fund allocation from nearly 18% to just 1%, reflecting uncertainty about sustainable growth in the near term [20]. Conclusion - The pharmaceutical and medical sectors are experiencing a mixed landscape, with certain areas like CXO and innovative drugs showing promise for growth, while IVD faces challenges from policy changes and market dynamics. The overall sentiment remains cautiously optimistic, with potential investment opportunities in recovering sectors.

Group 1 - Kexin Technology plans to repurchase shares worth between 30 million and 50 million yuan, with a maximum repurchase price of 80 yuan per share, for employee stock ownership plans or capital reduction [1] - Jiahua Technology's shareholder plans to reduce holdings by up to 1.5% of the company's total shares, amounting to a maximum of 116,000 shares, between May 28, 2025, and August 25, 2025 [1] - Beiqi Blue Valley's subsidiary reported cumulative sales of 38,041 vehicles this year, representing a year-on-year increase of 192.53% [2] Group 2 - AVIC Finance plans to transfer shares of AVIC Xi'an Aircraft Industry Group and AVIC Onboard Systems, totaling 4.067 billion yuan, to its controlling shareholder [2] - Haide shares' executives plan to increase their holdings by at least 20.73 million yuan within six months [3] - Dabeinong's subsidiary received planting approval for genetically modified soybeans in Brazil, marking significant progress in the South American market [4] Group 3 - Yongan Pharmaceutical's chairman is under investigation, but the company's operations remain normal [4] - Teruid's subsidiary is expected to win a 126 million yuan project from the State Grid, which will enhance the company's brand and industry influence [4][5] - Junxin shares plan to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 30.57 yuan per share [5] Group 4 - Meinian Health plans to reduce its holdings by up to 3% of the company's total shares, amounting to a maximum of 11.7 million shares, starting from May 27, 2025 [7] - Electric Power Investment is planning a major asset restructuring, leading to a temporary suspension of its stock [9] - Tongda shares are expected to win a 207 million yuan project from the State Grid, which will positively impact future operating performance [10] Group 5 - Xintian Technology's major shareholder plans to reduce holdings by up to 3% of the company's total shares, amounting to a maximum of 580,410 shares [11] - Huizhou Intelligent's controlling shareholder and some executives plan to increase their holdings by between 29.2 million and 58.4 million yuan [12] - Zhongdali De plans to sell a 50% stake in Shanghai Ketaike Transmission System Co., Ltd. for 9.2777 million yuan to optimize its asset structure [14] Group 6 - Jinlitai's stock will be suspended due to the inability to disclose periodic reports within the statutory deadline [15] - Chuhuan Technology's major shareholder plans to reduce holdings by up to 3% of the company's total shares, amounting to a maximum of 239,560 shares [15] - Guilin Sanjin's subsidiary received approval for clinical trials of a new indication for a monoclonal antibody injection [16] Group 7 - Plit plans to sign a strategic supply agreement for sodium-ion batteries, committing to supply at least 1 GWh over four years [17] - Dalian Electric Porcelain's subsidiary is expected to win a project worth approximately 71 million yuan from the State Grid [18]

Core Viewpoint - A hospital in Nanjing is under investigation for allegedly providing illegal assisted reproductive services, prompting a joint investigation team to be established by local health authorities [1] Group 1: Investigation Details - The Nanjing Qinhuai District Health Commission initiated an investigation on May 4 after media reports surfaced regarding the hospital's activities [1] - The investigation includes measures such as on-site inquiries, sealing relevant documents, and inspecting and confiscating related medical equipment [1] - Authorities have committed to thoroughly investigating any illegal activities and will handle violations in accordance with the law [1]